Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos

Background: The dose of oral anticoagulants (OAC) shows great variability among patients. Pharmacogenetic studies have shown that common variants in genes CYP2C9 (*2 and *3) and VKORC1 (-1639G>A) are associated with lower requirements of OAC. Aim: To study the association between average maintena...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benavides,Felipe, Grossman,Nicole, Poggi,Helena, Nieto,Elena, Bertrán,Antonio, Araos,Daniel, Vásquez,Marcos, Ibarra,Ignaz, Cáceres,Felipe, Espinoza,Karena, Lagos,Marcela, Repetto M,Gabriela
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2015
Materias:	Acenocoumarol Cytochrome P-450 CYP2C Pharmacogenetics VKORC1, protein, human Warfarin
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015001100001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872015001100001
record_format	dspace
spelling	oai:scielo:S0034-988720150011000012016-01-19Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenosBenavides,FelipeGrossman,NicolePoggi,HelenaNieto,ElenaBertrán,AntonioAraos,DanielVásquez,MarcosIbarra,IgnazCáceres,FelipeEspinoza,KarenaLagos,MarcelaRepetto M,Gabriela Acenocoumarol Cytochrome P-450 CYP2C Pharmacogenetics VKORC1, protein, human Warfarin Background: The dose of oral anticoagulants (OAC) shows great variability among patients. Pharmacogenetic studies have shown that common variants in genes CYP2C9 (2 and 3) and VKORC1 (-1639G>A) are associated with lower requirements of OAC. Aim: To study the association between average maintenance doses of oral anticoagulant therapy required to maintain a stable INR and CYP2C9 and VKORC1 gene variants in Chilean adults. Material and Methods: Prospective study of patients on anticoagulant treatment and with a stable international normalized ratio (INR) for prothrombin time for at least three months. Patients were classified as having high or low acenocoumarol or warfarin requirements. Peripheral blood DNA genotyping was performed by polymerase chain reaction and restriction fragment polymorphism or sequencing and electrophoresis. Results: The study included 185 patients, 125 on acenocoumarol and 60 on warfarin. Patients with VKORC1-1639A allele were more likely to require lower doses of both drugs than patients with the G allele (Odds ratio [OR] for acenocoumarol 9.06, and OR for warfarin = 18.7). There was no association between CYP2C92 and3 and acenocoumarol or warfarin requirements. Conclusions: There is an association between VKORC1-1639A variant and anticoagulant doses.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.11 20152015-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015001100001es10.4067/S0034-98872015001100001
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Acenocoumarol Cytochrome P-450 CYP2C Pharmacogenetics VKORC1, protein, human Warfarin
spellingShingle	Acenocoumarol Cytochrome P-450 CYP2C Pharmacogenetics VKORC1, protein, human Warfarin Benavides,Felipe Grossman,Nicole Poggi,Helena Nieto,Elena Bertrán,Antonio Araos,Daniel Vásquez,Marcos Ibarra,Ignaz Cáceres,Felipe Espinoza,Karena Lagos,Marcela Repetto M,Gabriela Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
description	Background: The dose of oral anticoagulants (OAC) shows great variability among patients. Pharmacogenetic studies have shown that common variants in genes CYP2C9 (2 and 3) and VKORC1 (-1639G>A) are associated with lower requirements of OAC. Aim: To study the association between average maintenance doses of oral anticoagulant therapy required to maintain a stable INR and CYP2C9 and VKORC1 gene variants in Chilean adults. Material and Methods: Prospective study of patients on anticoagulant treatment and with a stable international normalized ratio (INR) for prothrombin time for at least three months. Patients were classified as having high or low acenocoumarol or warfarin requirements. Peripheral blood DNA genotyping was performed by polymerase chain reaction and restriction fragment polymorphism or sequencing and electrophoresis. Results: The study included 185 patients, 125 on acenocoumarol and 60 on warfarin. Patients with VKORC1-1639A allele were more likely to require lower doses of both drugs than patients with the G allele (Odds ratio [OR] for acenocoumarol 9.06, and OR for warfarin = 18.7). There was no association between CYP2C92 and3 and acenocoumarol or warfarin requirements. Conclusions: There is an association between VKORC1-1639A variant and anticoagulant doses.
author	Benavides,Felipe Grossman,Nicole Poggi,Helena Nieto,Elena Bertrán,Antonio Araos,Daniel Vásquez,Marcos Ibarra,Ignaz Cáceres,Felipe Espinoza,Karena Lagos,Marcela Repetto M,Gabriela
author_facet	Benavides,Felipe Grossman,Nicole Poggi,Helena Nieto,Elena Bertrán,Antonio Araos,Daniel Vásquez,Marcos Ibarra,Ignaz Cáceres,Felipe Espinoza,Karena Lagos,Marcela Repetto M,Gabriela
author_sort	Benavides,Felipe
title	Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
title_short	Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
title_full	Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
title_fullStr	Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
title_full_unstemmed	Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
title_sort	efecto de las variantes de vkorc1 y cyp2c9 sobre la dosis de anticoagulantes orales en individuos chilenos
publisher	Sociedad Médica de Santiago
publishDate	2015
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015001100001
work_keys_str_mv	AT benavidesfelipe efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT grossmannicole efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT poggihelena efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT nietoelena efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT bertranantonio efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT araosdaniel efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT vasquezmarcos efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT ibarraignaz efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT caceresfelipe efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT espinozakarena efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT lagosmarcela efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos AT repettomgabriela efectodelasvariantesdevkorc1ycyp2c9sobreladosisdeanticoagulantesoralesenindividuoschilenos
_version_	1718436850680463360

Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos

Ejemplares similares